FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With Ntrk Gene Fusion-Positive Solid Tumors
FDA授予Repotrectinib加速批准,用於Ntrk基因融合陽性固體腫瘤的成人和兒童患者
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With Ntrk Gene Fusion-Positive Solid Tumors
FDA授予Repotrectinib加速批准,用於Ntrk基因融合陽性固體腫瘤的成人和兒童患者
譯文內容由第三人軟體翻譯。